articleThe LancetJan 16, 2012GREEN OA

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

JBJosé BaselgaIBIan BradburyHEHolger EidtmannSDSerena Di CosimoEDEvandro de Azambuja

Mass General Brigham · Massachusetts General Hospital · +24 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,312
total citations
FWCI
80.26
Percentile
100%
References
35
Citations per year

Authors

27

Topics & keywords

Topics
Keywords
  • Lapatinib
  • Trastuzumab
  • Medicine
  • Breast cancer
  • Internal medicine
  • Regimen
  • Clinical endpoint
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding